Skip to main content

Advertisement

SpringerLink
Log in

Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks

  • Brief Report
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. McCormick MC, Shapiro S, Starfield BH (1980) Rehospitalization in the first year of life for high-risk survivors. Paediatrics 66:991–999

    CAS  Google Scholar 

  2. American Academy of Paediatrics (1998) Prevention of respiratory syncytial virus infections: indications for use of palivizumab and update on the use of RSV–IGIV. Paediatrics 102:1211-1216

    Article  Google Scholar 

  3. Zaknun D, Resch B, Jürgenssen O, et al (2001) Prevention of respiratory syncytial virus (RSV) infection in preterm infants with palivizumab (Synagis). Monatsschr Kinderheilkd 149:176–178

    Google Scholar 

  4. Resch B, Gusenleitner W, Mandl C, Müller W (2000) Epidemiology of respiratory syncytial virus infection in southern Austria. Pediatr Infect Dis J 9:587–588

    Article  Google Scholar 

  5. Groothuis JR, Simoes EAF, Levin MJ, and the RSVIG Study Group (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329:1524–1530

    Article  PubMed  CAS  Google Scholar 

  6. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, for the Munich RSV Study Group (2003) Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 162:230–236

    PubMed  Google Scholar 

  7. Simoes EAF, Groothuis JR (2002) Respiratory syncytial virus prophylaxis the story so far. Respir Med 96 (Suppl B):15-24

    Google Scholar 

  8. Arnold SR, Wang EEL, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatr Infect Dis J 18:866–869

    Article  PubMed  CAS  Google Scholar 

  9. Parnes C, Guillermin J, Habersang R, et al (2003) Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from the palivizumab outcome registry. Pediatr Pulmonol 35:484-489

    Article  PubMed  Google Scholar 

  10. Sáez-Llorens X, Castaño E, Null D, et al (1998) Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia: the MEDI-493 Study Group. Pediatr Infect Dis J 17:787–791

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The Austrian RSV 29–32 Study Group includes the following members: A. Winder, Department of Paediatrics, Bregenz; C. Mann, Department of Paediatrics, Feldkirch; B. Resch, W. Gusenleitner, W.D. Müller, Department of Paediatrics, University Hospital, Graz; G. Grässl, Department of Paediatrics, University Hospital, Innsbruck; R. Papek, Department of Paediatrics, Kirchdorf; G. Frey, W. Kaulfersch, Department of Paediatrics, Klagenfurt; A. Herzog, Department of Paediatrics, Krems; G. Schweintzger, I. Mutz, Department of Paediatrics, Leoben; R. Piberhofer, Department of Paediatrics, Linz; M. Kundt, Department of Paediatrics, University Hospital, Salzburg; M. Weissensteiner, M. Altenriederer, Department of Paediatrics, Sankt Pölten; G. Schadenböck-Kranzl, Department of Paediatrics, Steyr; A. Schalk, Department of Paediatrics, Villach; W. Zissler, Department of Paediatrics, Vöcklabruck; A. Schneider, Department of Paediatrics, Wels; K. Klebermass, Arnold Pollack, Department of Paediatrics, AKH Wien, University Hospital, Vienna; J. Berger, A. Lischka, Department of Paediatrics, Glanzing, Vienna; R. Schafhauser, Department of Paediatrics, Preyersches Kinderspital, Vienna; W. Sterniste, Department of Paediatrics, SMZ Ost, Vienna; Z. Janos, P. Schermann, Department of Paediatrics, Zwettl.

Author information

Authors and Affiliations

  1. Division of Neonatology, Department of Paediatrics, Medical University Graz, Auenbruggerplatz 30, 8036, Graz, Austria

    B. Resch, W. Gusenleitner & W. D. Müller

  2. Medical Statistics, Department of Gynaecology and Obstetrics, Medical University Graz, Graz, Austria

    J. Haas

Authors
  1. B. Resch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Gusenleitner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. D. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Resch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Resch, B., Gusenleitner, W., Müller, W.D. et al. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25, 120–122 (2006). https://doi.org/10.1007/s10096-005-0082-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-005-0082-y

Keywords

Search

Navigation